5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Self-citationModulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
“…and Scherle, 2006 5-fluorouracil (small molecule) DNA NOA Inhibits pyrimidine metabolism, incorporation in to DNA and RNA causes cell-cycle arrest Longley et al., 2003 ABT-737, ABT-263 (small molecule) BCL-XL, BCL-2 OA Bind to the BH3 pocket of Bcl-XL and inhibit its antiapoptotic function…”
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
“Numerous pre-clinical studies have demonstrated that TS expression is a key determinant of 5-FU sensitivity [41].”
BackgroundSelf-citationThe ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
“incorporate in RNA and DNA and inhibit TS, is a cytotoxic agent widely used in the treatment of colorectal and breast cancers, as well as cancers of the aerodigestive tract (21).”
BackgroundNanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
“Thus, TS expression acted as a key determinant of 5-FU sensitivity [62] while in vitro studies have validated the association between TS expression and apoptosis 5-FU [63, 64] while the improved response rates of 5-FU-based chemotherapy were observed in patients with low tumour TS expression [65, 66].”
BackgroundRetractedDomingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Serine and one-carbon metabolism in cancer
Yang, M., & Vousden, K. H. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.81 · Cited by 992
Regulation of mammalian nucleotide metabolism and biosynthesis
Lane, A. N., & Fan, T. W.-M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv047 · Cited by 959
“Despite its functional importance, nucleotide metabolism and cell cycle control have received much less attention than genomics and functional genomics, although there have been multiple metabolic targets derived from the relevant processes for human disease therapy, such as the antimetabolites MTX (32,33), gemcitabin…”
Background5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Metabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
“5-FU is converted to three main active metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine triphosphate (FUTP) (Longley et al., 2003).”
Background5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
Zhang, N., Yin, Y., Xu, S.-J., & Chen, W.-S. (2008) · Molecules · doi:10.3390/molecules13081551 · Cited by 771
“Leucovorin (LV), which enters the cell via the reduced folate carriers and is anabolized to CH2THF, increases the intracellular CH2THF pool, thereby enhancing TS inhibition by FdUMP [30].”
BackgroundInfluentialBruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
Zeolitic imidazolate framework-8 as efficient pH-sensitive drug delivery vehicle
Sun, C.-Y., Qin, C., Wang, X.-L., Yang, G.-S., Shao, K.-Z., Lan, Y.-Q., Su, Z.-M., Huang, P., Wang, C.-G., & Wang, E.-B. (2012) · Dalton Transactions · doi:10.1039/c2dt30357d · Cited by 710
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
“synthetase is an enzyme used to generate thymidine monophosphate, which is subsequently phosphorylated to thymidine triphosphate for use in DNA synthesis and repair [164].”
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Cantor, J. R., Abu-Remaileh, M., Kanarek, N., Freinkman, E., Gao, X., Louissaint, A., Lewis, C. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.023 · Cited by 616
“Fluorodeoxyuridine monophosphate (FdUMP) leads to cell death by inhibition of thymidylate synthase (TYMS) (Longley et al., 2003).”
BackgroundInfluentialWang, L., Cho, K. B., Li, Y., Tao, G., Xie, Z., & Guo, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225758 · Cited by 605
“5-FU inhibits the nucleotide synthetic enzyme thymidylate synthase (TYMS) and incorporates its metabolites into DNA and RNA, which leads to the inhibition of the DNA synthesis and the disruption of RNA processing and post-transcriptional modification in cancer cells [113].”
BackgroundZhao, M., Perry, J. M., Marshall, H., Venkatraman, A., Qian, P., He, X. C., Ahamed, J., & Li, L. (2014) · Nature Medicine · doi:10.1038/nm.3706 · Cited by 607
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
“Examples include alkylating agents such as platinum compounds (DNA crosslinking) (Kelland, 2007), base-substituting agents such as 5-fluorouracil (recognized as base damage) (Longley et al., 2003), and topoisomerase inhibitors such as camptothecin and topotecan (inhibition of DNA replication) (Pommier, 2006).”
BackgroundSethy, C., & Kundu, C. N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111285 · Cited by 539
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
“Since this process is a critical source of thymidine, and cancer cells need elevated levels of thymidine to replicate, use of 5-FU is highly effective (Longley et al., 2003; Santi et al., 1987).”
BackgroundPharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
“TS expression is a key predictor of 5-FU activity [Longley et al. 2003], and its expression has long been recognized as a primary determinant of resistance [Berger et al.”
BackgroundDuffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., & Topolcan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 506
Tonga, G. Y., Jeong, Y., Duncan, B., Mizuhara, T., Mout, R., Das, R., Kim, S. T., Yeh, Y.-C., Yan, B., Hou, S., et al. (2015) · Nature Chemistry · doi:10.1038/nchem.2284 · Cited by 497
Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
Sargent, D. J., Conley, B. A., Allegra, C., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.112 · Cited by 499
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities
Nombela, P., Miguel-López, B., & Blanco, S. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01263-w · Cited by 492
“While the mechanism of action for active metabolites of 5’FU has been always attributed to disruption of both DNA and RNA syntheses and DNA damage induction [302], 5’FU was shown to inhibit pseudouridine synthases, due to the substitution of uracil by the analogue 5’FU in RNAs [303, 304].”
BackgroundPersonalized Mapping of Drug Metabolism by the Human Gut Microbiome
Javdan, B., Lopez, J. G., Chankhamjon, P., Lee, Y.-C. J., Hull, R., Wu, Q., Wang, X., Chatterjee, S., & Donia, M. S. (2020) · Cell · doi:10.1016/j.cell.2020.05.001 · Cited by 474
“Capecitabine is one of several generations of antimetabolite chemotherapeutic agents, many of which are prodrugs for 5-FU, and are known collectively as the oral fluoropyrimidines (FPs) (Lamont and Schilsky, 1999; Longley et al., 2003).”
BackgroundChemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
“5-fluorouracil (5-FU) is metabolized primarily in the liver and seems to accumulate in hepatocytes, where uracil analogues can interfere with RNA synthesis directly and DNA synthesis by inhibiting conversion of dUMP to dTMP [37,86].”
BackgroundHuang, X., Li, Z., Zhang, Q., Wang, W., Li, B., Wang, L., Xu, Z., Zeng, A., Zhang, X., Zhang, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0969-3 · Cited by 476
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
Lum, P. Y., Armour, C. D., Stepaniants, S. B., Cavet, G., Wolf, M. K., Butler, J. S., Hinshaw, J. C., Garnier, P., Prestwich, G. D., Leonardson, A., et al. (2004) · Cell · doi:10.1016/s0092-8674(03)01035-3 · Cited by 481
“In addition, that the antiproliferation effects of 5FU may result fromwe found that tricyclic antidepressants and tamoxifen inhibition of RNA metabolism (Longley et al., 2003).”
BackgroundShibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., & Hirohashi, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.082 · Cited by 468
Dong, S., Liang, S., Cheng, Z., Zhang, X., Luo, L., Li, L., Zhang, W., Li, S., Xu, Q., Zhong, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02229-6 · Cited by 458
“Several mechanisms of 5-FU resistance have been reported, including changes in the rate of drug influx or efflux [52], intra-tumor heterogeneity [52], epigenetic factors [53], tumor microenvironment [54], and 5-FU metabolic enzymes [55].”
BackgroundNoncoding RNAs in gastric cancer: implications for drug resistance
Wei, L., Sun, J., Zhang, N., Zheng, Y., Wang, X., Lv, L., Liu, J., Xu, Y., Shen, Y., & Yang, M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01185-7 · Cited by 468
Lei, Z., Tan, I. B., Das, K., Deng, N., Zouridis, H., Pattison, S., Chua, C., Feng, Z., Guan, Y. K., Ooi, C. H., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.010 · Cited by 458
Stem cell function and stress response are controlled by protein synthesis
Blanco, S., Bandiera, R., Popis, M., Hussain, S., Lombard, P., Aleksic, J., Sajini, A., Tanna, H., Cortés-Garrido, R., Gkatza, N., et al. (2016) · Nature · doi:10.1038/nature18282 · Cited by 466
B Vitamins and One-Carbon Metabolism: Implications in Human Health and Disease
Lyon, P., Strippoli, V., Fang, B., & Cimmino, L. (2020) · Nutrients · doi:10.3390/nu12092867 · Cited by 437
The multifaceted role of reactive oxygen species in tumorigenesis
Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452
Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels
Burger, K., Mühl, B., Harasim, T., Rohrmoser, M., Malamoussi, A., Orban, M., Kellner, M., Gruber-Eber, A., Kremmer, E., Hölzel, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.074211 · Cited by 458
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30686-7 · Cited by 444
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh305 · Cited by 435
“An important finding from our study is that PPI pretreatment predisposes melanoma and adenocarcinoma cells to the effects of different classes of antitumor agents, including cisplatin, whose mechanism of resistance is poorly known; 5-FU, whose main resistance mechanism is thought to be based on gene mutation ( 53 ); a…”
BackgroundSung, J. H., & Shuler, M. L. (2009) · Lab on a Chip · doi:10.1039/b901377f · Cited by 431
Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431
“There were several attempts to increase the efficiency of CD/5-FC therapy by achieving higher conversion of prodrug 5-FC to 5-FU and the toxic metabolites production.”
BackgroundInfluentialChemotherapy: a double-edged sword in cancer treatment
Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 397
Reversal of cytosolic one-carbon flux compensates for loss of the mitochondrial folate pathway
Ducker, G. S., Chen, L., Morscher, R. J., Ghergurovich, J. M., Esposito, M., Teng, X., Kang, Y., & Rabinowitz, J. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.016 · Cited by 419
“These include DHFR (dihydrofolate reductase), an enzyme strongly inhibited by current antifolates, and TYMS (thymidylate synthase), the target of the important chemotherapeutic 5-fluorouracil (Huennekens, 1994; Longley et al., 2003).”
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer
Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2822 · Cited by 418
Metabolism of pancreatic cancer: paving the way to better anticancer strategies
Qin, C., Yang, G., Yang, J., Ren, B., Wang, H., Chen, G., Zhao, F., You, L., Wang, W., & Zhao, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01169-7 · Cited by 413
Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00209 · Cited by 409
Stress granules, P-bodies and cancer
Anderson, P., Kedersha, N., & Ivanov, P. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.009 · Cited by 409
“5-FU is used for treatment of various types of cancers including breast, colorectal, head and neck cancers [103].”
BackgroundTargeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
Self-citationMicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)
Valeri, N., Gasparini, P., Braconi, C., Paone, A., Lovat, F., Fabbri, M., Sumani, K. M., Alder, H., Amadori, D., Patel, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015541107 · Cited by 382
“However, primary or acquired resistance to pyrimidine analog treatments is a common problem in the management of CRC patients (2).”
BackgroundInfluentialZhao, D., Tan, S., Yuan, D., Lu, W., Rezenom, Y. H., Jiang, H., Wang, L., & Zhou, H. (2011) · Advanced Materials · doi:10.1002/adma.201003012 · Cited by 378
Weiss, J. T., Dawson, J. C., Macleod, K. G., Rybski, W., Fraser, C., Torres-Sánchez, C., Patton, E. E., Bradley, M., Carragher, N. O., & Unciti-Broceta, A. (2014) · Nature Communications · doi:10.1038/ncomms4277 · Cited by 359
Plant flavonoids in cancer chemoprevention: role in genome stability
George, V. C., Dellaire, G., & Rupasinghe, H. P. V. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.11.007 · Cited by 362
RNA modifications regulating cell fate in cancer
Delaunay, S., & Frye, M. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0319-0 · Cited by 365
Polymeric nanoparticles‐based topical delivery systems for the treatment of dermatological diseases
Zhang, Z., Tsai, P., Ramezanli, T., & Michniak‐Kohn, B. B. (2013) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1211 · Cited by 357
Nanotechnology approaches for inhalation treatment of lung diseases
Kuzmov, A., & Minko, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.024 · Cited by 352
“Fluorouracil or 5-FU (trademarked as Adrucil, Carac, Efudex and Efudix) is a pyrimidine analog that acts primarily as a thymidylate synthase inhibitor to block synthesis of the pyrimidine thymidine and therefore interferes with DNA replication and inhibits cancer growth [122].”
Nuclear export of proteins and drug resistance in cancer
Turner, J. G., Dawson, J., & Sullivan, D. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.016 · Cited by 350
HDAC inhibitors: Clinical update and mechanism-based potential
Glaser, K. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.04.007 · Cited by 348
“Resistance to 5-FU is a common reason for treatment failure, especially in the treatment of colorectal cancers [63].”
BackgroundInfluential5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation
Cho, Y.-H., Ro, E. J., Yoon, J.-S., Mizutani, T., Kang, D.-W., Park, J.-C., Il Kim, T., Clevers, H., & Choi, K.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-19173-2 · Cited by 336
Wei, L., Wang, X., Lv, L., Liu, J., Xing, H., Song, Y., Xie, M., Lei, T., Zhang, N., & Yang, M. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1086-z · Cited by 339
Interference in Bacterial Quorum Sensing: A Biopharmaceutical Perspective
Rémy, B., Mion, S., Plener, L., Elias, M., Chabrière, E., & Daudé, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00203 · Cited by 332
“Finally, the anti-cancer drug (Longley et al., 2003), 5-FU, a pyrimidine analog (Figure 3), was demonstrated to inhibit QS-regulated virulence in P. aeruginosa in vitro (Ueda et al., 2009) and was further used for the coating of functionalized catheters, which were shown to be efficient during…”
MethodSqueezing for Life – Properties of Red Blood Cell Deformability
Huisjes, R., Bogdanova, A., van Solinge, W. W., Schiffelers, R. M., Kaestner, L., & van Wijk, R. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00656 · Cited by 321
“5-FU is a pyrimidine antagonist (Longley et al., 2003) and since purine and pyrimidines play key roles in cellular metabolism and energy homeostasis.”
BackgroundAstrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression
Yoo, B. K., Emdad, L., Su, Z.-Z., Villanueva, A., Chiang, D. Y., Mukhopadhyay, N. D., Mills, A. S., Waxman, S., Fisher, R. A., Llovet, J. M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36460 · Cited by 328
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells
Sasaki, K., Tsuno, N. H., Sunami, E., Tsurita, G., Kawai, K., Okaji, Y., Nishikawa, T., Shuno, Y., Hongo, K., Hiyoshi, M., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-370 · Cited by 322
“Intracellular metabolites of 5-FU can exert cytotoxic effects via inhibition of thymidylate synthetase, or through incorporation into RNA and DNA, events that ultimately activate apoptosis [2].”
BackgroundLee, C., Safdie, F. M., Raffaghello, L., Wei, M., Madia, F., Parrella, E., Hwang, D., Cohen, P., Bianchi, G., & Longo, V. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3228 · Cited by 324
Zhang, S., Yang, Y., Weng, W., Guo, B., Cai, G., Ma, Y., & Cai, S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0985-y · Cited by 316
Sex Differences in Cancer: Epidemiology, Genetics and Therapy
Kim, H.-I., Lim, H., & Moon, A. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.103 · Cited by 315
“In the treatment of various cancers, 5-FU has been widely used as an effective chemotherapy (Longley et al., 2003).”
BackgroundDNA mismatch repair and the DNA damage response
Li, Z., Pearlman, A. H., & Hsieh, P. (2016) · DNA Repair · doi:10.1016/j.dnarep.2015.11.019 · Cited by 307
Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis
Vyas, D., Laput, G., & Vyas, A. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60114 · Cited by 310
“66 However, its clinical use is hampered because of drug resistance 67 and induction of intestinal damage, referred to as intestinal mucositis, the most significant dose-limiting toxicity.”
BackgroundOn-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology
Chou, D. B., Frismantas, V., Milton, Y., David, R., Pop-Damkov, P., Ferguson, D., MacDonald, A., Vargel Bölükbaşı, Ö., Joyce, C. E., Moreira Teixeira, L. S., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0495-z · Cited by 294
Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules
Vigderman, L., & Zubarev, E. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.004 · Cited by 305
“Another interesting example of anticancer drug that has been conjugated to gold nanoparticles is 5-fluorouracil, a drug which inhibits DNA and RNA synthesis [119].”
BackgroundThe Influence of Cell Cycle Regulation on Chemotherapy
Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136923 · Cited by 290
“For example, FDUMP, the active form of 5-FU, can inhibit TS and induce DNA damage (Figure 3) [53].”
BackgroundCo-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles
Li, L., Gu, W., Chen, J., Chen, W., & Xu, Z. P. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.095 · Cited by 304
“5-FU has been used against cancers for over 40 years and acts principally as a thymidylate synthase inhibitor [4].”
BackgroundRecent advances (2015–2016) in anticancer hybrids
Kerru, N., Singh, P., Koorbanally, N., Raj, R., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.033 · Cited by 295
Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway
Deisenroth, C., & Zhang, Y. (2010) · Oncogene · doi:10.1038/onc.2010.189 · Cited by 302
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
GSDME mediates caspase-3-dependent pyroptosis in gastric cancer
Wang, Y., Yin, B., Li, D., Wang, G., Han, X., & Sun, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.156 · Cited by 299
Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells
Li, J., Hou, N., Faried, A., Tsutsumi, S., Takeuchi, T., & Kuwano, H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0260-0 · Cited by 291
“Its mechanism of cytotoxicity has been ascribed to the misincorporation of fluoronucleotides into RNA and DNA and the inhibition of the nucleotide synthetic enzyme thymidylate synthase.(9) In our experiment, we used two kinds of colon cancer cells, colon26 (a mouse-derived colon carcinoma cell line) and HT29 (a human-…”
BackgroundMethodImmunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 294
“5-fluorouracil (5-FU), the most common of the chemotherapeutic agents for CRC, acts through inhibition of thymidylate synthase, which converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), causing DNA damage [47].”
BackgroundProteome Integral Solubility Alteration: A High-Throughput Proteomics Assay for Target Deconvolution
Gaetani, M., Sabatier, P., Saei, A. A., Beusch, C. M., Yang, Z., Lundström, S. L., & Zubarev, R. A. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00500 · Cited by 287
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
Chattopadhyay, S., Moran, R. G., & Goldman, I. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0343 · Cited by 281
“cytotoxicity, and the spectrum and limitations of their clinical effects (98).”
BackgroundDäster, S., Amatruda, N., Calabrese, D., Ivanek, R., Turrini, E., Droeser, R. A., Zajac, P., Fimognari, C., Spagnoli, G. C., Iezzi, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13857 · Cited by 281
Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium
Pentinmikko, N., Iqbal, S., Mana, M., Andersson, S., Cognetta, A. B., Suciu, R. M., Roper, J., Luopajärvi, K., Markelin, E., Gopalakrishnan, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1383-0 · Cited by 271
Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0538-7 · Cited by 270
Dendrimers: A New Race of Pharmaceutical Nanocarriers
Mittal, P., Saharan, A., Verma, R., Altalbawy, F. M. A., Alfaidi, M. A., Batiha, G. E.-S., Akter, W., Gautam, R. K., Uddin, M. S., & Rahman, M. S. (2021) · BioMed Research International · doi:10.1155/2021/8844030 · Cited by 257
“As a result of which, the solubility and controlled discharge of medicaments get increased [38].”
Background5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Miura, K., Kinouchi, M., Ishida, K., Fujibuchi, W., Naitoh, T., Ogawa, H., Ando, T., Yazaki, N., Watanabe, K., Haneda, S., et al. (2010) · Cancers · doi:10.3390/cancers2031717 · Cited by 260
“Despite this information about the activity of 5-FU, the molecular mechanisms downstream of TS inhibition still have to be confirmed [8].”
BackgroundInfluentialEmerging therapies in cancer metabolism
Xiao, Y., Yu, T.-J., Xu, Y., Ding, R., Wang, Y.-P., Jiang, Y.-Z., & Shao, Z.-M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.006 · Cited by 256
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Niesel, J., Pinto, A., Peindy N'Dongo, H. W., Merz, K., Ott, I., Gust, R., & Schatzschneider, U. (2008) · Chemical Communications · doi:10.1039/b719075a · Cited by 267
Epigenetics and Colorectal Cancer Pathogenesis
Bardhan, K., & Liu, K. (2013) · Cancers · doi:10.3390/cancers5020676 · Cited by 252
“Although it was developed more than 50 years ago, 5-FU is still the backbone of treatment for patients with colorectal cancer, especially metastatic colorectal cancer [205,240].”
BackgroundInfluential
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.